logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
2H 2021
Aridis Pharmaceuticals Inc
Data from Phase IIa trial of AR-501
Cystic fibrosis
2H 2021
Aridis Pharmaceuticals Inc
Top-line data from phase III pivotal trial of AR-301
Acute pneumonia caused by S. aureus infection
2H 2021
PhaseBio Pharmaceuticals Inc
Results from Phase 2b clinical trial of PB1046
Pulmonary Arterial Hypertension
2H 2021
Summit Therapeutics plc
Top-line data from phase III trial of Ridinilazole (Ri-CoDIFy 1)
C. difficile infection
2H 2021
Summit Therapeutics plc
Top-line data from phase III trial of Ridinilazole (Ri-CoDIFy 2)
C. difficile infection
2H 2021
MIRAGEN THERAPEUTICS, INC.
Primary endpoint data from phase II trial of Cobomarsen ( SOLAR)
Mycosis fungoides (MF)
Q3 2021
Xenon Pharmaceuticals Inc.
Top-line results from phase IIb study of XEN1101 as adjunctive treatment
Focal epilepsy in adults
2H 2021
ERYTECH Pharma S.A
Final analysis from Phase 3 clinical trial evaluating the efficacy and safety of eryaspase(TRYbeCA-1)
Advanced metastatic pancreatic cancer
2H 2021
MacroGenics Inc.
Data from final overall survival analysis of the SOPHIA study of Margetuximab
HER2-positive metastatic breast cancer
2H 2021
Mereo BioPharma Group plc
Top-line data from phase II study of Alvelestat
Alpha-1 antitrypsin deficiency (AATD)
Q3 2021
Outlook Therapeutics, Inc.
Safety and efficacy data from phase III study of ONS-5010 (NORSE 2 )
wet age-related macular degeneration(wet AMD)
2H 2021
Kaleido Biosciences
Topline data from Phase 2 trial of KB195 (UNLOCKED)
Topline data from Phase 2 trial of KB195 (UNLOCKED)
2H 2021
Adverum Biotechnologies Inc.
Clinical data from phase 2 Clinical Trial of ADVM-022 (INFINITY)
Diabetic Macular Edema
2H 2021
Matinas BioPharma Holdings, Inc.
Topline data from phase 2 trial of MAT2203 ( EnACT)
Invasive fungal infections, including cryptococcal meningitis
2H 2021
Allakos Inc.
Topline data from phase 3 study of AK002
Eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD)
2H 2021
Allakos Inc.
Topline data from phase 2/3 study of AK002
Eosinophilic esophagitis (EoE)
2H 2021
Arcutis Biotherapeutics Inc.
Topline data from Phase 2b study of ARQ-151
Atopic dermatitis
Q3 2021
Atara Biotherapeutics, Inc.
Finalize Submission of BLA for tab-cel
EBV+ PTLD (Post transplant lymphoproliferative disease)
Q3 2021
ImmunityBio, Inc
Interim data from phase 2 trial of PD-L1 t-haNK
Non-Small Cell Lung Cancer 3rd line treatment
2H 2021
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of Imfinzi
Adjuvant bladder; liver (locoregional); biliary tract
cancer
2H 2021
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of Imfinzi + tremelimumab (POSEIDON)
First-line treatment of patients with Non-small cell lung cancer (NSCLC)
2H 2021
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of Lynparza (PROfound)
metastatic castration-resistant prostate cancer (mCRPC)
2H 2021
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of Enhertu (DESTINY-Breast01)
HER2-breast cancer
2H 2021
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of acalabrutinib vs. ibrutinib(ELEVATE-TN)
Patients with previously-treated high-risk chronic lymphocytic leukaemia (CLL)
2H 2021
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of (DELIVER)
Heart Failure with preserved ejection fraction(HFpEF)